Literature DB >> 16356335

Simultaneous and sensitive analysis of THC, 11-OH-THC, THC-COOH, CBD, and CBN by GC-MS in plasma after oral application of small doses of THC and cannabis extract.

Thomas Nadulski1, Frank Sporkert, Martin Schnelle, Andreas M Stadelmann, Patrik Roser, Tom Schefter, Fritz Pragst.   

Abstract

Besides the psychoactive Delta(9)-tetrahydrocannabinol (THC), hashish and marijuana as well as cannabis-based medicine extracts contain varying amounts of cannabidiol (CBD) and of the degradation product cannabinol (CBN). The additional determination of these compounds is interesting from forensic and medical points of view because it can be used for further proof of cannabis exposure and because CBD is known to modify the effects of THC. Therefore, a method for the simultaneous quantitative determination of THC, its metabolites 11-hydroxy-Delta(9)-tetrahydrocannabinol (11-OH-THC) and 11-nor-9-carboxy-Delta(9)-tetrahydrocannabinol (THC-COOH), CBD and CBN from plasma was developed. The method was based on automatic solid-phase extraction with C(18) ec columns, derivatization with N,O-bistrimethylsilyltrifluoroacetamide (BSTFA), and gas chromatography-electron impact ionization-mass spectrometry (GC-EI-MS) with deuterated standards. The limits of detection were between 0.15 and 0.29 ng/mL for THC, 11-OH-THC, THC-COOH, and CBD and 1.1 ng/mL for CBN. The method was applied in a prospective pharmacokinetic study after single oral administration of 10 mg THC alone or together with 5.4 mg CBD in cannabis extract. The maximum plasma concentrations after cannabis extract administration ranged between 1.2 and 10.3 ng/mL (mean 4.05 ng/mL) for THC, 1.8 and 12.3 ng/mL (mean 4.9 ng/mL) for 11-OH-THC, 19 and 71 ng/mL (mean 35 ng/mL) for THC-COOH, and 0.2 and 2.6 ng/mL (mean 0.95 ng/mg) for CBD. The peak concentrations (mean values) of THC, 11-OH-THC, THC-COOH, and CBD were observed at 56, 82, 115, and 60 min, respectively, after intake. CBN was not detected. Caused by the strong first-pass metabolism, the concentrations of the metabolites were increased during the first hours after drug administration when compared to literature data for smoking. Therefore, the concentration ratio 11-OH-THC/THC was discussed as a criterion for distinguishing oral from inhalative cannabis consumption.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16356335     DOI: 10.1093/jat/29.8.782

Source DB:  PubMed          Journal:  J Anal Toxicol        ISSN: 0146-4760            Impact factor:   3.367


  32 in total

Review 1.  Human cannabinoid pharmacokinetics.

Authors:  Marilyn A Huestis
Journal:  Chem Biodivers       Date:  2007-08       Impact factor: 2.408

2.  Ultra-high performance liquid chromatography tandem mass-spectrometry for simple and simultaneous quantification of cannabinoids.

Authors:  Rohitash Jamwal; Ariel R Topletz; Bharat Ramratnam; Fatemeh Akhlaghi
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2017-02-06       Impact factor: 3.205

3.  Determination of ∆-9-Tetrahydrocannabinol (THC), 11-hydroxy-THC, 11-nor-9-carboxy-THC and Cannabidiol in Human Plasma using Gas Chromatography-Tandem Mass Spectrometry.

Authors:  David M Andrenyak; David E Moody; Matthew H Slawson; Daniel S O'Leary; Margaret Haney
Journal:  J Anal Toxicol       Date:  2017-05-01       Impact factor: 3.367

4.  Self-administration of edible Δ9-tetrahydrocannabinol and associated behavioral effects in mice.

Authors:  Michael P Smoker; Ken Mackie; Christopher C Lapish; Stephen L Boehm
Journal:  Drug Alcohol Depend       Date:  2019-04-17       Impact factor: 4.492

Review 5.  Bioanalytical procedures for monitoring in utero drug exposure.

Authors:  Teresa Gray; Marilyn Huestis
Journal:  Anal Bioanal Chem       Date:  2007-03-17       Impact factor: 4.142

6.  Oral fluid and plasma cannabinoid ratios after around-the-clock controlled oral Δ(9)-tetrahydrocannabinol administration.

Authors:  Garry Milman; David M Schwope; Eugene W Schwilke; William D Darwin; Deanna L Kelly; Robert S Goodwin; David A Gorelick; Marilyn A Huestis
Journal:  Clin Chem       Date:  2011-08-29       Impact factor: 8.327

7.  Simultaneous GC-EI-MS determination of Delta9-tetrahydrocannabinol, 11-hydroxy-Delta9-tetrahydrocannabinol, and 11-nor-9-carboxy-Delta9-tetrahydrocannabinol in human urine following tandem enzyme-alkaline hydrolysis.

Authors:  Tsadik T Abraham; Ross H Lowe; Stephane O Pirnay; William D Darwin; Marilyn A Huestis
Journal:  J Anal Toxicol       Date:  2007-10       Impact factor: 3.367

8.  Simultaneous quantification of cannabinoids and metabolites in oral fluid by two-dimensional gas chromatography mass spectrometry.

Authors:  Garry Milman; Allan J Barnes; Ross H Lowe; Marilyn A Huestis
Journal:  J Chromatogr A       Date:  2010-01-04       Impact factor: 4.759

9.  Acute Δ(9)-tetrahydrocannabinol blocks gastric hemorrhages induced by the nonsteroidal anti-inflammatory drug diclofenac sodium in mice.

Authors:  Steven G Kinsey; Erica C Cole
Journal:  Eur J Pharmacol       Date:  2013-06-11       Impact factor: 4.432

10.  Simultaneous quantification of Delta9-tetrahydrocannabinol, 11-hydroxy-Delta9-tetrahydrocannabinol, and 11-nor-Delta9-tetrahydrocannabinol-9-carboxylic acid in human plasma using two-dimensional gas chromatography, cryofocusing, and electron impact-mass spectrometry.

Authors:  Ross H Lowe; Erin L Karschner; Eugene W Schwilke; Allan J Barnes; Marilyn A Huestis
Journal:  J Chromatogr A       Date:  2007-07-06       Impact factor: 4.759

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.